MindBio’s Voice AI Targets Mining Safety in South America

MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) is advancing its voice-based artificial intelligence platform for detecting drug and alcohol impairment, targeting industrial safety in South America’s mining sector. The biotechnology company recently appointed Chilean policy specialist Felipe Leyton to lead commercialization efforts in the region, signaling a transition from technology development to field implementation. Leyton brings experience in national drug policy and workplace safety, having helped design and implement Chile’s ‘Zero Tolerance’ alcohol-impaired driving law and establishing the country’s roadside drug testing program in 2019. His appointment aligns with MindBio’s strategy to integrate technical development with regulatory and industry expertise in markets where impairment detection is critical for workplace safety and compliance.

MindBio’s AI prediction model uses over 50 million data points to predict alcohol intoxication with high accuracy using only the human voice. The company is developing an enterprise platform including Edge-AI kiosks with bespoke hardware and software for detecting drug and alcohol intoxication in environments such as mining, aviation, construction, and law enforcement. This technology has the potential to revolutionize safety protocols by enabling non-invasive, real-time impairment screening.

The company was featured in a recent article highlighting its commercial deployment efforts, focusing on South America’s mining sector. The full article is available at https://ibn.fm/JBNVq. For more updates on MindBio, visit the company’s newsroom at https://ibn.fm/MBQIF.